This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Merle A. Sande, MD
University of California—San Francisco

JAMA. 1994;271(23):1830.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—I appreciate Dr Weiss' comments regarding the NIAID consensus panel's published recommendations dealing with antiretroviral therapy. Acquired immunodeficiency syndrome research is clearly in a period in which understanding of how the virus replicates and causes disease has not been translated effectively to the bedside. Treating this viral infection early certainly makes intuitive sense, especially since active replication occurs in the lymph nodes¹ (even though clinically silent) and nucleoside resistance develops more rapidly in later stages of the disease,² but data derived from clinical trials to date just do not show a significant survival benefit.³

When to treat HIV infection and with which agent(s) is obviously a difficult clinical decision. However, the recent report by Lenderking et al⁴ certainly underscores the potential downside with regard to quality of life when taking zidovudine. That is why the NIAID convened a group of thoughtful clinicians and statisticians . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?